Leptospira interrogans serovar icterohaemorrhagiae seropositivity and the reproductive performance of sows

The reproductive performance of 28 sows seropositive to Leptospira interrogans serovar icterohaemorrhagiae was compared with that of 87 Leptospira sp. seronegative dams belonging to the same herd. Sows were sampled during 1988 to 1993. During this period the herd was not submitted to any kind of intervention (antibiotic therapy, immunoprophylaxis or rodent control). Relative risks (RR) of return to heat, mummified fetuses, stillbirth, and weak newborn piglets for infected sows were assessed and the differences in means of total piglets born per litter, piglets born alive, piglets effectively housed, weaned piglets, stillbirths, mummified fetuses, weak newborn piglets, weight at birth of the piglets effectively housed, weight at 21 days of life and weight at weaning were evaluated. Seropositive dams had a greater risk of having weak newborn piglets (RR = 1.67, 1.02 < or = CI 95% < or = 2.72) and also of having more weak newborn piglets per litter (P = 0.01). Other variables examined were not different (P > 0.05).

Immunotherapy for porcine cysticercosis: implications for prevention of human disease. Cysticercosis Working Group in Peru

Taenia solium cysticercosis is an important cause of human disease in many developing countries. Porcine cysticercosis is a vital link in the transmission of this disease and impairs meat production. A treatment for porcine cysticercosis may be an effective way of preventing human disease that would also benefit pig farmers, facilitating control programs in disease-endemic regions. Previous research suggests that reinfection with cysticercosis or immunotherapy with cysticercal antigens may cause degeneration of cysticerci, potentially curing porcine cysticercosis. Therefore, a blinded, randomized, controlled study to assess the efficacy and safety of immunotherapy in 28 naturally parasitized pigs was performed. Four groups of pigs with similar weights were inoculated twice with membrane-enriched cysticercal antigens (MA), saline, aqueous-soluble crude cysticercal antigens (AA) in adjuvant (Freund's complete then incomplete), or adjuvant alone. Immunotherapy was well tolerated but had no consistent effect on the macroscopic appearance of cysticerci or eosinophil count. Histopathologic findings were variable, with both severe and minimal inflammatory reactions seen in adjacent cysticerci in all pigs. Nine (64%) of 14 pigs given immunotherapy developed new antibody bands on electroimmunotransfer blot compared with one (7%) of 14 control pigs (P < 0.01). Treatment with AA in adjuvant caused a significant increase in the proportion of cysticerci that failed to evaginate and were, therefore, not viable for infecting humans (34% for pigs given AA in adjuvant compared with 10% for adjuvant alone; P < 0.04). Although immunotherapy caused a statistically significant decrease in the viability of cysticerci, this immunologic reaction was not great enough to prevent human disease.

[Specific immunotherapy of canine atopy. A prospective clinical study using tyrosine adsorbents]

It is reported about a non-randomized prospective study of the treatment of 17 atopic dogs over a nine-months-period using tyrosine-precipitated vaccines. All dogs were presented because of perennial atopic skin diseases at a practice for internal medicine between 1992 and 1995. The clinical degree of pruritus and dermatitis was controlled before, after three, six, and nine months of immunotherapy individually. After nine months of immunotherapy five dogs showed a reduction of the symptoms for more than 75%, six dogs for more than 50%, six dogs for less than 50%. Eleven (65%) dogs were classified as having been successfully treated, six (35%) showed poor clinical response. Tyrosine-precipitated vaccines were found to be helpful in the treatment of atopic skin diseases of the dog.

Canine osteosarcoma: amputation and chemoimmunotherapy

Canine osteosarcoma is a highly metastatic cancer commonly seen in large breed dogs. At the time of diagnosis, approximately 90% to 95% of the dogs have established micrometastases. Dogs undergoing amputation alone have a median survival time of 3 to 4 months. Amputation followed by cisplatin chemotherapy increases median survival times to 9 to 11 months. When dogs are treated with amputation and cisplatin, followed by immunotherapy (with liposome-encapsulated muramyl tripeptide phosphatidylethanolamine), median survival times increase to 14.4 months, the longest reported median survival time for dogs with osteosarcoma treated by amputation and any form of adjuvant therapy.

Chemoimmunotherapy of canine lymphoma with adjuvant canine monoclonal antibody 231

Chemoimmunotherapy with adjuvant CL/MAb 231 offers an alternative treatment approach for canine lymphoma. Results of treatment and prognostic factors are discussed and compared with previously published chemotherapy results.

Caring for the retrovirus infected cat

No commercial vaccine [correction of vacine] exists for feline immunodeficiency virus (FIV), and although feline leukemia virus (FeLV) vaccines are available, they are neither 100% effective nor used in all cats. These realities clearly indicate the veterinarian will be required to treat either FeLV- or FIV-positive cats for some time to come. The management of FIV- or FeLV-positive cats may require supportive therapies as well as virus-specific therapies such as zidovudine (AZT; Retrovir, Burroughs Wellcome, Research Triangle Park, NC).

Anti-inflammatory and immune support in endotoxemia and septicemia

Endotoxemia and septicemia are encountered frequently in equine veterinary practice. The deleterious effects of endotoxin are related to the severity of the response of the host's inflammatory system. Consequently, it is imperative that appropriate steps be taken to identify animals at risk of developing endotoxemia or septicemia, and to initiate treatments that will reduce the inflammatory response. This article discusses the anti-inflammatory and immune support of horses and foals with endotoxemia and septicemia.

Antitumor effect of locally injected low doses of recombinant human interleukin-2 in bovine vulval papilloma and carcinoma

In many human clinical trials and in various animal tumor models, the antitumor effect of high doses of systemically applied interleukin-2 (IL-2) is tested. Our studies focused on the effects of low doses of locally injected IL-2. In this paper, the effect of local injection of low doses of IL-2, i.e. a total dose of 25,000-50,000 units, into papillomas or carcinomas of the bovine vulva is described. In 19 out of 23 (83%) cows treated with IL-2 an effect on the tumor load was observed; in three of these animals, complete regression was obtained. In the majority of cases, regression was not restricted to the tumors injected with IL-2.

Immunization and immunotherapy for mastitis

Immunization and immunotherapy for mastitis are active areas of investigation. The past decade has seen development of effective and economical R-mutant vaccines for gram-negative mastitis. These vaccines doubtless will prove beneficial on well managed dairies that have eradicated contagious mastitis pathogens. Development of vaccines for other mastitis pathogens has been noticeably slower. A commercially available Staphylococcus aureus vaccine appears to reduce the frequency and severity of clinical episodes, but probably has minimal impact on the incidence or prevalence of infection. This product has not been extensively studied. The recent recognition of virulence factors produced in vivo by Staphylococcus aureus may provide a breakthrough in the development and production of Staphylococcus aureus vaccines. Bacterins employing this principle presently are not commercially available, however. In the case of all contagious mastitis pathogens (Streptococcus agalactiae, Staphylococcus aureus, and Mycoplasma spp.), traditional control and eradication efforts (teat dip, dry cow therapy, culling programs) likely will prove preferable to long-term immunization. Ongoing research may provide more efficacious vaccines for these mastitis syndromes. Immunostimulants are an active area of research. Although leukopoietic factors appear promising as immunostimulants, no compound has clearly demonstrated efficacy in either the prevention or treatment of bovine mastitis.

[The paraspecific immune defense: possibilities and limits]

The paraspecific defense system is the phylogenetically older part of the complex immune system. It enables the organism to immediately attack various foreign substances, infectious germs and toxins when confronted by them. In order to activate the paraspecific immune system with the help of drugs, so-called "paramunity inducers" are employed. The use of paramunization is a new way of prophylaxis and therapy, not only with regard to infections, but also with regard to different other indications. The limitations of paramunization are to be found in genetic defects of the paraspecific immune system, therefore the success of paramunization is dependent on the functioning of the paraspecific defense system. The possibility of developing paramunity inducers that are pyrogen-free, non-toxic and pleotypically effective in pre-clinical and clinical experiments is illustrated through the use of pox and parapox viruses. Inducers based on different pox virus species were effective and safe when used in humans as well as in animals in the field.

The treatment of multicentric canine lymphoma

Canine LSA is a fatal disease if untreated, but fortunately it is also a disease that is very responsive to therapeutic intervention. It is likely that most cases seen and treated by practitioners will be managed with the currently effective drugs and with new protocols as they are developed. Other approaches, including immunotherapy and BMT, are likely to remain more in the arena of the academic institution but should be available in the referral setting for appropriate cases. Great strides have been made in the less than 30 years that canine LSA has been widely treated; it is reasonable that similar progress is to be expected in the years to come.

Perioperative medical care for equine abdominal surgery

Rational perioperative management improves the success rate of abdominal surgery. Important aspects of management are discussed, including principles of fluid therapy, nutrition, intravenous catheterization, antimicrobial prophylaxis, and the use of nonsteroidal anti-inflammatory medication. Current advances in the area of immunotherapy are mentioned.

In vitro immune monitoring of antibody response in dogs given chemoimmunotherapy for lymphoma

Clinical remission in 30 dogs with lymphoma was induced with a combination of vincristine, L-asparaginase, cyclophosphamide, and doxorubicin HCl, administered sequentially, and then an autochthonous tumor cell vaccine, given intralymphatically, as maintenance therapy. Humoral antibody amounts were monitored in 11 dogs, using a solid-phase bead-type radioimmunoassay. The median survival of the 30 dogs was 13 months from the start of chemotherapy (range, 7 to 25 months; mean, 13.8). The median remission duration was 16 weeks (range, 9 to 98 weeks; mean, 26.8). Correlation between increase in amount of humoral antibody was significant (P = 0.0001 to 0.012), before and after chemoimmunotherapy, in dogs responding to therapy, compared with that in dogs not responding to therapy.

Propionibacterium acnes immunotherapy in chronic recurrent canine pyoderma. An adjunct to antibiotic therapy

In a randomized, double-blind, placebo-controlled study, dogs with chronic recurrent pyoderma were treated with antibiotics plus intravenous injections of either Propionibacterium acnes or placebo. Responses (an increase, decrease, or clearing of lesions) were measured and evaluated statistically. Eighty percent (12 of 15) of the dogs treated with antibiotics and P acnes compared with 38% (five of 13) of the dogs treated with antibiotics and placebo responded with significant improvement or complete remission of lesions at the end of the 12-week treatment schedule (P less than 0.05).

Current experimental therapy

For successful experimental therapy of canine hematopoietic tumors, one must have a randomized homogeneous population of patients in reasonably good condition. Drug combinations should contain several agents, each with antitumor effect, acceptable toxicity, and of reasonable cost. Other modalities include biological response modifiers, radiation, differentiation-inducing agents, and marrow transplantation. Ways must be found to prevent drug resistance of tumor cells.

Immunomodulation of hematopoietic tumors

Immunotherapy has been used in a variety of hematopoietic and solid tumors. Because patients with leukemia and lymphoma are immunosuppressed, immunomodulation with chemotherapy may be beneficial. Chemoimmunotherapy of canine lymphoma is discussed.